These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 36732801)
1. Leveraging process mining for modeling progression trajectories in amyotrophic lateral sclerosis. Tavazzi E; Gatta R; Vallati M; Cotti Piccinelli S; Filosto M; Padovani A; Castellano M; Di Camillo B BMC Med Inform Decis Mak; 2023 Feb; 22(Suppl 6):346. PubMed ID: 36732801 [TBL] [Abstract][Full Text] [Related]
2. A Dynamic Bayesian Network model for the simulation of Amyotrophic Lateral Sclerosis progression. Zandonà A; Vasta R; Chiò A; Di Camillo B BMC Bioinformatics; 2019 Apr; 20(Suppl 4):118. PubMed ID: 30999865 [TBL] [Abstract][Full Text] [Related]
3. Mapping of critical events in disease progression through binary classification: Application to amyotrophic lateral sclerosis. Dalgıç ÖO; Wu H; Safa Erenay F; Sir MY; Özaltın OY; Crum BA; Pasupathy KS; J Biomed Inform; 2021 Nov; 123():103895. PubMed ID: 34450286 [TBL] [Abstract][Full Text] [Related]
4. Different patterns of spreading direction and motor neurons involvement in a cohort of limb-onset amyotrophic lateral sclerosis patients from Southern Italy: Potential implication on disease course or progression? Milella G; Zoccolella S; Urso D; Nigro S; Tamburrino L; Gnoni V; Filardi M; Logroscino G Brain Behav; 2023 Jun; 13(6):e2899. PubMed ID: 37208847 [TBL] [Abstract][Full Text] [Related]
5. Deep learning methods to predict amyotrophic lateral sclerosis disease progression. Pancotti C; Birolo G; Rollo C; Sanavia T; Di Camillo B; Manera U; Chiò A; Fariselli P Sci Rep; 2022 Aug; 12(1):13738. PubMed ID: 35962027 [TBL] [Abstract][Full Text] [Related]
6. Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression. Karanevich AG; Statland JM; Gajewski BJ; He J BMC Med Res Methodol; 2018 Feb; 18(1):19. PubMed ID: 29409450 [TBL] [Abstract][Full Text] [Related]
11. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. Abdul Wahid SF; Law ZK; Ismail NA; Lai NM Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962 [TBL] [Abstract][Full Text] [Related]
12. Model-Based and Model-Free Techniques for Amyotrophic Lateral Sclerosis Diagnostic Prediction and Patient Clustering. Tang M; Gao C; Goutman SA; Kalinin A; Mukherjee B; Guan Y; Dinov ID Neuroinformatics; 2019 Jul; 17(3):407-421. PubMed ID: 30460455 [TBL] [Abstract][Full Text] [Related]
13. Cognitive and behavioural impairment in amyotrophic lateral sclerosis: A landmark of the disease? A mini review of longitudinal studies. Consonni M; Dalla Bella E; Bersano E; Lauria G Neurosci Lett; 2021 May; 754():135898. PubMed ID: 33862143 [TBL] [Abstract][Full Text] [Related]
14. Swallowing Safety and Efficiency Impairment Profiles in Individuals with Amyotrophic Lateral Sclerosis. Robison R; DiBiase L; Ashley A; McElheny K; Anderson A; Wymer JP; Plowman EK Dysphagia; 2022 Jun; 37(3):644-654. PubMed ID: 34037850 [TBL] [Abstract][Full Text] [Related]
15. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study. Deeb O; Nabulsi M Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341 [TBL] [Abstract][Full Text] [Related]